Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... communication has been the topic of fascination since the era ... and the Soviet Russia. Earlier even a small ...
(Date:1/23/2015)... and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) has announced ... or Foley Catheters, Intermittent Catheters and Male External or ... Trends and Forecast 2014 - 2020" report to ... global market for urinary catheters is experiencing a healthy ...
(Date:1/23/2015)... 2015  A new analysis of Centers for Medicare and ... shows that 81 percent of seniors chose lower-cost preferred ... at certain pharmacies. The findings were released by ... now the foundation of Medicare Part D," said Pharmaceutical ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... 9, 2011 CardioFocus, Inc., developer of the HeartLight ... Fibrillation (AF), announced its technology enables a Pulmonary Vein ... 86% of PVs remaining persistently isolated after three months. ... durable freedom from AF after a single procedure. ...
... Texas, May 9, 2011 Lexicon Pharmaceuticals, Inc. ... hold its Annual R&D Day on Thursday, May 12, 2011 ... York, New York.  Members of Lexicon,s senior management team will ... overview of several other preclinical programs in the company,s pipeline. ...
Cached Medicine Technology:New Studies Support CardioFocus HeartLight™ Endoscopic Ablation System's Notable Treatment Results for Paroxysmal Atrial Fibrillation 2New Studies Support CardioFocus HeartLight™ Endoscopic Ablation System's Notable Treatment Results for Paroxysmal Atrial Fibrillation 3Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day 2
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... When it comes to cosmetic,injectables, the terms "investigational" ... The Physicians Coalition for,Injectable Safety offers consumers these ... consumer safety information is required by,the Food and ... has been,approved," explained Coalition leader Roger Dailey, MD ...
... of the most exciting scientific and clinical areas. Every ... rulings by regulatory bodies, or ethical controversies often ... as well as ethicists, legislators, the media and the ... more than 5,000 of the worlds leading experts in ...
... ... WHO: Antonio Garcia from Frost & Sullivan,s Healthcare Consulting ... Image Management Consultants, will share industry ... volumes of medical images and protecting ...
... CEO, and Chairman Issues Shareholder Letter, ... CEO and Chairman of BioElectronics, Corp. (Pink ... anti-inflammatory patch,with an embedded battery operated microchip ... and speed healing, today issued the,following letter ...
... Teleconference to be Held at 8:30 a.m. EDT, ... (Nasdaq: FFHL ) (,Fuwei, or ,the Company,), a,manufacturer ... announced the financial results for the fourth quarter and ... Highlights, -- Revenues for 2007 rose 2.9% to ...
... A new member-based,organization, Practice Greenhealth, has ... Practice Greenhealth reflects the combined experience,of three ... of,the healthcare sector: Hospitals for a Healthy ... and the Healthcare Clean Energy Exchange., ...
Cached Medicine News:Health News:Clarity on Cosmetic Injectable Labeling and Use 2Health News:Clarity on Cosmetic Injectable Labeling and Use 3Health News:European Society of Human Reproduction & Embryology 24th annual meeting 2Health News:Protecting Patient Images From Damage and Disaster 2Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 2Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 3Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 4Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 2Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 3Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 4Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 5Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 6Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 7Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 8Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 9Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 10Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 11Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 12Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 13Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 14Health News:Practice Greenhealth Hires First Exec 2
McIntyre-Binkhorst, length 18 mm....
Binkhorst, length 35 mm....
Wilbrandt-Binkhorst Cannula have a smooth blunt tip end opening....
Army/Navy retractor (set of 2)....
Medicine Products: